Table 1 EC50 values obtained using two independent assays.

From: Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation

Drug(s)

Total inhibition of HIV-1 PR (EC50, nM)

Inhibition of HIV-1 PR precursor (EC50, nM)

Antiviral activity (EC50, nM)

Darunavir

8.5 ± 1.5

133 ± 7

4.3 ± 0.5

Atazanavir

10.8 ± 3.6

937 ± 171

1.4 ± 0.1

Nelfinavir

21 ± 6

1302 ± 59

10.8 ± 1.0

Darunavir + Atazanavir 1:1

7.3 ± 3.6

242 ± 32

0.7 ± 0.1

Nelfinavir + Atazanavir 1:1

8.2 ± 2.3

706 ± 44

0.5 ± 0.1

  1. The total PR inhibition and precursor PR inhibition were quantified using HEK293T cells transiently transfected with the mCherry-PRprec-EGFP reporter. In parallel, antiviral activity was determined with MT4 cell-based CPE protection assay with NL4-3 virus. The error was expressed as a standard error.
Back to article page